We found that malignant melanoma can be stratified into at least two subgroups based on promoter methylation status, and that High‐methylation subgroup involving TFPI2 methylation exhibits advanced tumor phenotypes, characterized by thicker progression and worse prognosis. The gene discussed is TFPI2; the disease is melanoma.